NASDAQ:ALKSAlkermes Stock Price, Forecast & News

Alkermes' stock was trading at $16.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALKS shares have increased by 14.5% and is now trading at $18.61.
View which stocks have been most impacted by COVID-19.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 8 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Alkermes.

Alkermes is scheduled to release its next quarterly earnings announcement on Wednesday, October 28th 2020.
View our earnings forecast for Alkermes.

Alkermes Plc (NASDAQ:ALKS) posted its earnings results on Wednesday, July, 29th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.19. The business had revenue of $247.53 million for the quarter, compared to analyst estimates of $232.70 million. Alkermes had a positive return on equity of 4.47% and a negative net margin of 10.87%. The business's revenue was down 11.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.09 earnings per share.
View Alkermes' earnings history.

Alkermes updated its FY20 earnings guidance on Wednesday, July, 29th. The company provided EPS guidance of $0.00-0.19 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.11. The company issued revenue guidance of $965-1.005 billion, compared to the consensus revenue estimate of $983.05 million.

10 equities research analysts have issued 12-month price targets for Alkermes' stock. Their forecasts range from $15.00 to $28.00. On average, they expect Alkermes' stock price to reach $19.80 in the next twelve months. This suggests a possible upside of 6.4% from the stock's current price.
View analysts' price targets for Alkermes.

Press coverage about ALKS stock has been trending positive this week, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alkermes earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term.
View the latest news about Alkermes.

Alkermes saw a increase in short interest in May. As of May 15th, there was short interest totaling 10,700,000 shares, an increase of 20.0% from the April 30th total of 8,920,000 shares. Based on an average daily trading volume, of 1,950,000 shares, the short-interest ratio is currently 5.5 days. Approximately 6.8% of the company's shares are sold short.
View Alkermes' Short Interest.

Some companies that are related to Alkermes include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Netflix (NFLX), AbbVie (ABBV), Gilead Sciences (GILD), NVIDIA (NVDA), Celgene (CELG), Pfizer (PFE), Starbucks (SBUX), Alibaba Group (BABA), Advanced Micro Devices (AMD) and Intel (INTC).

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Alkermes' stock is owned by a number of institutional and retail investors. Top institutional shareholders include First Trust Advisors LP (2.52%), UBS Group AG (1.24%), Goldman Sachs Group Inc. (1.11%), Russell Investments Group Ltd. (0.50%), Meditor Group Ltd (0.47%) and Bank of New York Mellon Corp (0.36%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Paul J Mitchell and Richard F Pops.
View institutional ownership trends for Alkermes.

ALKS stock was sold by a variety of institutional investors in the last quarter, including Meditor Group Ltd, Federated Hermes Inc., Rhenman & Partners Asset Management AB, Alps Advisors Inc., New York State Common Retirement Fund, Amalgamated Bank, Arizona State Retirement System, and California Public Employees Retirement System. Company insiders that have sold Alkermes company stock in the last year include Iain Michael Brown, Michael J Landine, and Richard F Pops.
View insider buying and selling activity for Alkermes.

ALKS stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, First Trust Advisors LP, MERIAN GLOBAL INVESTORS UK Ltd, Goldman Sachs Group Inc., WINTON GROUP Ltd, Russell Investments Group Ltd., Principal Financial Group Inc., and Hardman Johnston Global Advisors LLC.
View insider buying and selling activity for Alkermes.

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALKS stock can currently be purchased for approximately $18.61.

Alkermes has a market capitalization of $2.96 billion and generates $1.17 billion in revenue each year. The company earns $-196,620,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. Alkermes employs 2,235 workers across the globe.

The official website for Alkermes is www.alkermes.com.

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]